Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses

Journal: Cancer Cell

Published: 2018-08-16

DOI: 10.1016/j.ccell.2018.07.012

Affiliations: 17

Authors: 38

Go to article
Institutions FC
Department of Computational Biology, St. Jude, United States of America (USA) 0.33
Department of Developmental Neurobiology, St. Jude, United States of America (USA) 0.16
Department of Pathology, St. Jude, United States of America (USA) 0.11
Department of Oncology, St. Jude, United States of America (USA) 0.09
Department of Structural Biology, St. Jude, United States of America (USA) 0.08
Center for Proteomics and Metabolomics, St. Jude, United States of America (USA) 0.08
Pharmacokinetics Shared Resource, St. Jude, United States of America (USA) 0.03
Department of Chemical Biology and Therapeutics, St. Jude, United States of America (USA) 0.03
McDonnell Genome Institute (MGI), WUSTL, United States of America (USA) 0.02
Department of Genetics, WUSTL, United States of America (USA) 0.02
College of Graduate Health Sciences (CGHS), UTHSC, United States of America (USA) 0.01
Department of Ophthalmology, UTHSC, United States of America (USA) 0.01
Department of Molecular and Cellular Biology, Arizona, United States of America (USA) 0.01
BIO5 Institute, Arizona, United States of America (USA) 0.01
Siteman Cancer Center, WUSTL, United States of America (USA) 0.01
John T. Milliken Department of Medicine, WUSTL, United States of America (USA) 0.01
Howard Hughes Medical Institute (HHMI), United States of America (USA) 0

Return